SCHEMBL15049982

SCHEMBL15049982

Cc1cc(C(=O)O)nn1Cc1cc(Br)ccc1OCC1CCCC1

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 20/20 0.67
CYP1A2 P05177 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15049977 0.98 PTGER1 (0.67) PTGER1CYP1A2
SCHEMBL15050019 0.89 PTGER1 (0.54) PTGER1CYP1A2
SCHEMBL15049986 0.88 PTGER1 (0.67) PTGER1
SCHEMBL15049945 0.87 PTGER1 (0.54) PTGER1CYP1A2
SCHEMBL252139 0.86 PTGER1 (0.50) PTGER1CYP1A2
SCHEMBL15050015 0.86 PTGER1 (0.61) PTGER1CYP1A2
SCHEMBL14956765 0.84 PTGER1 (0.50) PTGER1CYP1A2
SCHEMBL14956206 0.84 PTGER1 (0.49) PTGER1CYP1A2
SCHEMBL4103280 0.84 PTGER1 (0.70) PTGER1CYP1A2
SCHEMBL4683931 0.81 PTGER1 (0.72) PTGER1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2966064-A1 PYRAZOLE-3-CARBOXYLIC ACID COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2016-01-13 EP claimed
US-9090566-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2015-07-28 US claimed
EP-2797894-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-11-05 EP claimed
WO-2013101733-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-04 WO claimed
US-20130165492-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 US claimed
US-9522890-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-12-20 US disclosed
US-9522890-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-12-20 US disclosed
US-9522890-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-12-20 US disclosed
US-20160068491-A1 COMPOUNDS AS TYROSINE KINASE MODULATORS ALLERGAN, INC. 2016-03-10 US disclosed
US-20160068491-A1 COMPOUNDS AS TYROSINE KINASE MODULATORS ALLERGAN, INC. 2016-03-10 US disclosed
US-20160068491-A1 COMPOUNDS AS TYROSINE KINASE MODULATORS ALLERGAN, INC. 2016-03-10 US disclosed
EP-2966064-A1 PYRAZOLE-3-CARBOXYLIC ACID COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2016-01-13 EP disclosed
US-9090566-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2015-07-28 US disclosed
US-9090566-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2015-07-28 US disclosed
EP-2797894-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-11-05 EP disclosed
WO-2013101733-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-04 WO disclosed
WO-2013101733-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-04 WO disclosed
US-20130165492-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 US disclosed
US-20130165492-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 US disclosed
US-20130165492-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165492-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PTGER1 1/4885CYP1A2 979/4885
US-20160068491-A1 COMPOUNDS AS TYROSINE KINASE MODULATORS PTGER4, PTGER1, GRK4 PTGER1 2/4885CYP1A2 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.